30 Years of Evidence
Featured Content
pancreatic cancer awareness
Investigating the Efficacy and Safety of the CyberKnife System for Treating Primary Pancreatic Cancer with Metastases to the Gastrointestinal Tract
pancreatic cancer awareness
Long-Term Outcomes of Ablative Stereotactic Body Radiation Therapy for Inoperable, Non-Metastatic Pancreatic Cancer
pancreatic cancer awareness
Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic Cancer
Efficacy and safety of stereotactic body radiation therapy for the treatment of pulmonary metastases from sarcoma: A potential alternative to resection
Baumann BC, Nagda SN, Kolker JD, Levin WP, Weber KL, Berman AT, Staddon A, Hartner L, Hahn SM, Glatstein E, Simone CB | J Surg Oncol. | 2016
Phase I Trial of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Ablative Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer
Kunos CA, Sherertz TM, Mislmani M, Ellis RJ, Lo SS, Waggoner SE, Zanotti KM, Herrmann K, Debernardo RL | Front Oncol | 2015
Stereotactic Body Radiotherapy for Recurrent or Oligometastatic Uterine Cervix Cancer: A Cooperative Study of the Korean Radiation Oncology Group (KROG 14-11)
Park HJ, Chang AR, Seo Y, Cho CK, Jang WI, Kim MS, Choi C | Anticancer Res | 2015
Stereotactic Radiotherapy in the Retreatment of Recurrent Cervical Cancers, Assessment of Toxicity, and Treatment Response: Initial Results and Literature Review
Pontoriero A, Iatì G, Aiello D, Pergolizzi S | Technol Cancer Res Treat | 2016
Long-term results of robotic radiosurgery for non brachytherapy patients with cervical cancer
Morgenthaler J, Köhler C, Budach V, Sehouli J, Stromberger C, Besserer A, Trommer M, Baues C, Marnitz S | Strahlenther Onkol | 2021
CyberKnife Stereotactic Ablative Radiotherapy for Recurrent or Oligometastatic Gynecological Cancers
Kataria T, Naga P, Banerjee S, Gupta D, Narang K, Tayal M, Bisht SS | South Asian J Cancer | 2021
Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints
Meier RM, Bloch DA, Cotrutz C, Beckman AC, Henning GT, Woodhouse SA, Williamson SK, Mohideen N, Dombrowski JJ, Hong RL, Brachman DG, Linson PW, Kaplan ID. | Int J Radiat Oncol Biol Phys | 2018
Patient and Dosimetric Predictors of Genitourinary and Bowel Quality of Life After Prostate SBRT: Secondary Analysis of a Multi-institutional Trial
Wang K, Chen RC, Kane B, Medbery CA, Underhill K, Gray JR, Peddada AV, Fuller DB | Int J Radiat Oncol Biol Phys | 2018
5-year Biochemical Outcomes of Stereotactic Body Radiotherapy with Intraprostatic Dose Escalation for Unfavorable Prostate Cancer
Blacksburg SR, Aghdam N, Royce TJ, Burri RJ, Obayomi-Davies O, Mezeckis M, Meier R, Fuller DB, Chen RC, Lanciano RM, Haas JA, Collins SP | Int J Radiat Oncol Biol Phys | 2019
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial
Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Henderson D, Brown S, Cruickshank C, Burnett S, Duffton A, Griffin C, Hinder V, Morrison K, Naismith O, Hall E, van As N; PACE Trial Investigators | Lancet Oncol | 2019
Prostate SBRT: Comparison the Efficacy and Toxicity of Two Different Dose Fractionation Schedules
Fuller DB, Naitoh J, Shirazi R, Crabtree T, Mardirossian G | Front Oncol | 2020
Favorable Biochemical Freedom From Recurrence With Stereotactic Body Radiation Therapy for Intermediate and High-Risk Prostate Cancer: A Single Institutional Experience With Long-Term Follow-Up
Ricco A, Barbera G, Lanciano R, Feng J, Hanlon A, Lozano A, Good M, Arrigo S, Lamond J, Yang J | Front Oncol | 2020
Acute side effects after definitive stereotactic body radiation therapy (SBRT) for patients with clinically localized or locally advanced prostate cancer: a single institution prospective study
Jorgo K, Polgar C, Stelczer G, Major T, Gesztesi L, Agoston P | Radiol Oncol | 2021
Bleeding Risk Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer in Men on Baseline Anticoagulant or Antiplatelet Therapy
Pepin A, Shah S, Pernia M, Lei S, Ayoob M, Danner M, Yung T, Collins BT, Suy S, Aghdam N, Collins SP | Front Oncol | 2021
Five-year outcomes of stereotactic body radiation therapy (SBRT) for prostate cancer: the largest experience in China
Zhao X, Ye Y, Yu H, Jiang L, Cheng C, Guo X, Ju X, Zhu X, Zhang H. | J Cancer Res Clin Oncol | 2021
1651: Stereotactic Body Radiotherapy for Localized Kidney Cancer Compared with Standard Surgery Within a Young Academic Urologists Working Group Database
Michele Aquilano et al. | ESTRO | 2025
1021: RE-START: A National Registry Including Patients Undergoing Reirradiation After Previous RT for Prostate Cancer. A Study on Behalf of AIRO
Giulio Francolini et al. | ESTRO | 2025
2454: Robotic Stereotactic Body Radiotherapy for Malignant Liver Lesions: Local Control and Overall Survival – a Mono Institutional Study
Mariam Zurabashvili et al. | ESTRO | 2025
540: Liver SBRT in More Than 4 Fractions: Local Control and Recurrence Patterns
Alizée Renan et al. | ESTRO | 2025
3765: Re-irradiation Experience: Is it Underused in XXI Century?
Escarlata López et al. | ESTRO | 2025
3732: Use of Stereotactic Body Radiotherapy (SBRT) for Spine Metastases with Robotic Radiosurgery Unit CyberKnife in Patients with Oligometastatic Disease
Adrián Durango Méndez et al. | ESTRO | 2025
3389: Analysis of Local Control and Pain Relief of Rib Metastases Treated with Stereotactic Body Radiotherapy
Chiara Mattioli et al. | ESTRO | 2025
2718: Gastro-intestinal Toxicity: NTCP Models Based on CT-guided Online Adaptive SBRT for Abdominal Lymph Node Oligometastases
Lucy A van Werkhoven et al. | ESTRO | 2025
